Date: 2012-11-05
Type of information: Grant
Company: Sentinel Oncology (UK)
Investors: Biomedical Catalyst Fund (UK)
Amount: £1.8m (€ 2.2 million)
Funding type: grant
Planned used: The award will help fund the development of new a drug to treat pancreatic cancer and ultimately achieve the aim of building a sustainable pipeline of products, growing the company to accommodate new drug discovery projects and ultimately discovering more new cancer drugs.
Others: Sentinel Oncology has been awarded an Early Stage grant as part of the government-backed Biomedical Catalyst funding initiative. The £180M Biomedical Catalyst is an integrated translational funding programme jointly operated by the Medical Research Council and the Technology Strategy Board providing responsive and effective support for the best life science opportunities arising in the UK. It was announced by the Prime Minister David Cameron in December 2011 as part of the UK Government’s Life Sciences Strategy.
Therapeutic area: Cancer - Oncology
